Foreign-Trade Zone (FTZ) 214, Notification of Proposed Production Activity; Patheon Manufacturing Services LLC; (Opdualag); Greenville, North Carolina

Primary source

Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.

Published

May 20, 2026

Issuing agencies

Commerce DepartmentForeign-Trade Zones Board

Full Text

<html>
<head>
<title>Federal Register, Volume 91 Issue 97 (Wednesday, May 20, 2026)</title>
</head>
<body><pre>
[Federal Register Volume 91, Number 97 (Wednesday, May 20, 2026)]
[Notices]
[Pages 29450-29451]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2026-10046]


-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE

Foreign-Trade Zones Board

[B-48-2026]


Foreign-Trade Zone (FTZ) 214, Notification of Proposed Production 
Activity; Patheon Manufacturing Services LLC; (Opdualag); Greenville, 
North Carolina

    Patheon Manufacturing Services LLC submitted a notification of 
proposed production activity to the FTZ Board (the Board) for its 
facility in Greenville, North Carolina within FTZ 214. The notification 
conforming to the

[[Page 29451]]

requirements of the Board's regulations (15 CFR 400.22) was received on 
May 14, 2026.
    Pursuant to 15 CFR 400.14(b), FTZ production activity would be 
limited to the specific foreign-status material(s)/component(s) and 
specific finished product(s) described in the submitted notification 
(summarized below) and subsequently authorized by the Board. The 
benefits that may stem from conducting production activity under FTZ 
procedures are explained in the background section of the Board's 
website--accessible via <a href="http://www.trade.gov/ftz">www.trade.gov/ftz</a>.
    The proposed finished products include: Opdualag (pre-filled 
syringes containing Relatlimab and Nivolumab in aqueous solution) 
(duty-free).
    The proposed foreign-status materials/components include: 
Relatlimab (an aqueous solution drug targeting immune checkpoint LAG-3 
in melanoma therapy); and Nivolumab-rmbw (an aqueous solution targeting 
immunotherapy treatment against cancer cells) (duty-free).
    The request indicates that certain materials/components are subject 
to duties under section 301 of the Trade Act of 1974 (section 301), 
depending on the country of origin. The applicable section 301 
decisions require subject merchandise to be admitted to FTZs in 
privileged foreign status (19 CFR 146.41).
    Public comment is invited from interested parties. Submissions 
shall be addressed to the Board's Executive Secretary and sent to: 
<a href="/cdn-cgi/l/email-protection#95f3e1efd5e1e7f4f1f0bbf2fae3"><span class="__cf_email__" data-cfemail="c3a5b7b983b7b1a2a7a6eda4acb5">[email&#160;protected]</span></a>. The closing period for their receipt is June 29, 2026.
    A copy of the notification will be available for public inspection 
in the ``Online FTZ Information System'' section of the Board's 
website.
    For further information, contact John Frye at <a href="/cdn-cgi/l/email-protection#074d686f692941757e6247737566636229606871"><span class="__cf_email__" data-cfemail="a4eecbccca8ae2d6ddc1e4d0d6c5c0c18ac3cbd2">[email&#160;protected]</span></a>.

    Dated: May 15, 2026.
Elizabeth Whiteman,
Executive Secretary.
[FR Doc. 2026-10046 Filed 5-19-26; 8:45 am]
BILLING CODE 3510-DS-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>

View on FederalRegister.gov →Plain-text source

Indexed from Federal Register on May 20, 2026.

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.